BAUSCH & LOMB PHARMA

Active

Public limited companyfounded 1989active for 36 yearsPlace Alphonse Bosch 19, 1300 Wavre, BelgiumKBO/BCE: BE 0439.621.618

Summary

BAUSCH & LOMB PHARMA has been active since 1989 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €751,241 and a net result of €871,860. Equity remains stable across the filed financial years (±0% per year). Its solvency ranks better than 12% of 6,141 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (low).

Risk analysisFollow Report Compare

BAUSCH & LOMB PHARMAActiveChecked score 79/100

Risk analysis Report Compare

Activity

Wholesale of pharmaceutical and medical goods

NACE 46460

2 sites

Size

€37.4mturnover 2025

Staff: 11.6 FTE
Equity: €751,241
Profit: €871,860

Financial health

79 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.5%

Structure

Parent: BAUSCH HEALTH COMPANIES INC.

Eberhard KuehneDirector

Auditor: PwC Reviseurs d'Entreprises2025 accounts 25 days early3 of 27 deeds summarised

Why 79raises riskEquity €751,241 (8.2% of total assets)1 change of registered office in 24 monthslowers riskSize: turnover €37.4m, 11.6 FTE, total assets €9.2mProfit of €871,860 (financial year 2025)Show the evidence

Checked score

Score 2025

79 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 31% of its sector peers (NACE 46, small)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 33-1

equity 8.2% of total assets

Liquidity 14+2

short-term debt 91.0% · cash 10.9%

Profitability 65-3

return on assets 9.5%

Bankruptcy probability, 12 months

0.5% Low

0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,374 companies, NACE 46, small)

Last 24 months 11-2024: 0.5% 12-2024: 0.5%● unchanged vs 11-2024 01-2025: 0.5%● unchanged vs 12-2024 02-2025: 0.5%● unchanged vs 01-2025 03-2025: 0.5%● unchanged vs 02-2025 04-2025: 0.4%▼ -0.1 percentage points vs 03-2025 05-2025: 0.4%● unchanged vs 04-2025 06-2025: 0.5%▲ +0.1 percentage points vs 05-2025 07-2025: 0.6%▲ +0.1 percentage points vs 06-2025highest value 08-2025: 0.2%▼ -0.4 percentage points vs 07-2025lowest value 09-2025: 0.2%● unchanged vs 08-2025lowest value 10-2025: 0.2%● unchanged vs 09-2025lowest value 11-2025: 0.2%● unchanged vs 10-2025 12-2025: 0.2%● unchanged vs 11-2025 01-2026: 0.2%● unchanged vs 12-2025 02-2026: 0.2%● unchanged vs 01-2026 03-2026: 0.2%● unchanged vs 02-2026 04-2026: 0.2%● unchanged vs 03-2026 05-2026: 0.2%● unchanged vs 04-2026 06-2026: 0.2%● unchanged vs 05-2026 07-2026: 0.2%● unchanged vs 06-2026 08-2026: 0.5%▲ +0.3 percentage points vs 07-2026 09-2026: 0.5%● unchanged vs 08-2026 10-2026: 0.5%● unchanged vs 09-2026

Credit of up to €55,000 on 30-day terms is acceptable

Liquidity tight (current ratio 1.03, compared with 1.06 in 2024, below the usual 1.5; short-term debt: 91% and cash: 10.9% of total assets), and 91.8% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small): better than 11% on solvency, 11% on liquidity, 53% on profitability and 48% on growth.

The bankruptcy probability was computed on 26-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises riskneutral

Equity €751,241 (8.2% of total assets)

NBB · annual accounts

1 change of registered office in 24 months

Belgian Official Gazette

Size: turnover €37.4m, 11.6 FTE, total assets €9.2m

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Profit of €871,860 (financial year 2025)

NBB · annual accounts

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 12% of 6141 sector peers (2025).

NBB · sector comparison

Position among 6141 sector peers

Solvency

better than 12%

← weakest strongest →

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-07-2026, 25 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

25 days early

2024

15 days early

2023

21 days early

2022

24 days early

2021

5 days early

2020

31 days late

2019

59 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average on the deadline day; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 11 July (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

27-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

22-07-2026 Registered office · Amendment of the…Registered-office move
06-07-2026 Annual accounts filedfinancial year 2025 · full…
14-08-2025 Reappointment: PwC Reviseurs d'Entreprises (statutory auditor)Permanent representative: Loris Guidi

Key points

Caution: Among the weakest 12% on solvencysector median 45.2% · 6,141 companies 8.2% View
Positive: 5 years of growth in a rowturnover 2025: €37.4m 5 years View
Controlled by BAUSCH HEALTH COMPANIES INC. parent View
Positive: Filed on time since financial year 2021accounts within the deadline every year 5 years View

By topic

Financials

Financial year: 2025
Turnover: €37.4m
Profit: €871,860
Solvency: 8.2%

Turnover▲ 4.7%

Net result

20182025

Go to Financials

Board & ownership

Board: 1 member
Parent: BAUSCH HEALTH COMPANIES INC.
Auditor: PwC Reviseurs d'Entreprises

Eberhard KuehneDirector

Go to Board & ownership

Timeline

Events: 42
Since: 1991
Next accounts: by 31-07-2027

16-07-2025Annual accounts filed
18-07-2024Reappointment: Eberhard Kuehne (director)
10-07-2024Annual accounts filed

Go to Timeline

Company details

Sites: 2

Legal form: Public limited company
Activity: Wholesale of pharmaceutical and medical goodsNACE 46460
Founded: 19-12-1989
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 5

Who signs: Two directors jointly

Go to Articles of association

Key facts about BAUSCH & LOMB PHARMA

What is the company number of BAUSCH & LOMB PHARMA?: 0439.621.618. In Belgium the VAT number is the company number with BE in front: BE 0439.621.618.
Where is BAUSCH & LOMB PHARMA based?: The registered office is at Place Alphonse Bosch 19, 1300 Wavre.Company details
What does BAUSCH & LOMB PHARMA do?: According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
What is the legal form of BAUSCH & LOMB PHARMA?: Public limited company (NV).
When was BAUSCH & LOMB PHARMA founded?: On 19-12-1989.
Is BAUSCH & LOMB PHARMA still active?: Yes, BAUSCH & LOMB PHARMA is an active enterprise in the KBO register.
How many employees does BAUSCH & LOMB PHARMA have?: On average 11.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of BAUSCH & LOMB PHARMA?: €37.4m in financial year 2025, according to the filed annual accounts.
Is BAUSCH & LOMB PHARMA profitable?: In financial year 2025, BAUSCH & LOMB PHARMA made a profit of €871,860.
Where can I find the annual accounts of BAUSCH & LOMB PHARMA?: BAUSCH & LOMB PHARMA filed 36 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BAUSCH & LOMB PHARMA due?: By 31-07-2027, for financial year 2026.Timeline